Results 171 to 180 of about 41,944 (264)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions [PDF]

, 2016
Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality.
Konecny, G, Kristeleit, RS
core  

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, Volume 86, Issue 6, Page 689-696, May 2026.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

Cancer Medicine
Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring ...
Michele Milella, Giulia Orsi, Mariacristina diMarco, Lisa Salvatore, Letizia Procaccio, Silvia Noventa, Silvia Bozzarelli, Ingrid Garajova, Enrico Vasile, Guido Giordano, Marina Macchini, Alessandro Cavaliere, Marina Gaule, Francesca Bergamo, Marta Chiaravalli, Andrea Palloni, Riccardo Carloni, Alessandro Bittoni, Monica Niger, Ilario Giovanni Rapposelli, Maria Grazia Rodriquenz, Mario Scartozzi, Stefania Mosconi, Elisa Giommoni, Ilaria Bernardini, Chiara Paratore, Andrea Spallanzani, Katia Bencardino, Laura Forti, Emiliano Tamburini, Sara Lonardi, Aldo Scarpa, Stefano Cascinu, Giampaolo Tortora, Isabella Sperduti, Michele Reni   +35 more
doaj   +1 more source

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 5, May 2026.
ABSTRACT Aim Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.
Yoh Watanabe, Tsukasa Baba, Shu Soeda, Hideki Tokunaga, Wataru Yamagami, Hiroyuki Nomura, Yoichi Kobayashi, Kei Kawana, Kiyoshi Yoshino, Yoshihito Yokoyama, Hirotaka Nishi, Hiroaki Kobayashi, Yukiko Matsuzawa, Shunsuke Oyamada, Satoru Takahashi, Satoru Nagase   +15 more
wiley   +1 more source

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2017
E. Pujade-Lauraine, J. Ledermann, F. Selle, V. Gebski, R. Penson, A. Oza, J. Korach, T. Huzarski, A. Poveda, S. Pignata, M. Friedlander, N. Colombo, P. Harter, K. Fujiwara, I. Ray-Coquard, Susana Banerjee, Joyce F. Liu, E. Lowe, R. Bloomfield, P. Pautier   +19 more
semanticscholar   +1 more source

Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. [PDF]

Molecules
Huang L, Yang Y, Duan D, Dai L, Zhai B, Qian B.   +5 more
europepmc   +1 more source

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [PDF]

J Immunother Cancer
Murray CE, Ontiveros CO, Wentworth J, Blinkiewicz P, Leung B, Bai H, Spicer N, Holtz A, Tanner C, Balasubramanian A, Li W, Dray E, Zhao W, Curiel TJ.   +13 more
europepmc   +1 more source

Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy. [PDF]

Front Oncol
Karakaya G.
europepmc   +1 more source

BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study. [PDF]

Front Oncol
Gao Y, Gai M, Zhang H, Li H.
europepmc   +1 more source